Multiple sclerosis arises from immune-mediated attack on myelin and oligodendrocytes in the central nervous system, causing demyelination and axonal loss.
Multiple sclerosis arises from immune-mediated attack on myelin and oligodendrocytes in the central nervous system, causing demyelination and axonal loss. Stem-cell strategies target both immune dysregulation and repair: placental mesenchymal stem cells are studied for their capacity to calm autoreactive immune cells and secrete neuroprotective factors, while neurogenic cells are explored for remyelination and axonal support. Preclinical work suggests stem cells migrate toward lesions and release anti-inflammatory mediators. Trials have enrolled relapsing-remitting and progressive forms, but the mechanism of any benefit is incompletely characterised, and no approach yet reverses established disability or halts long-term progression in humans.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €4,140–€92,000 (getlabtest.com, cellmedicine.com) |
| Main cell types studied | MSCs from Amniotic Membrane, Neurogenic Cells |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 92 · 14 recruiting now |
For the clinic's own description, see how Stem Plus describes its Multiple Sclerosis programme ↗.
Ninety-two registered trials and 14 recruiting studies investigate stem-cell therapy in MS, across Europe, Asia and North America. Small series describe reduced relapse rates or stable disability scores; some show fewer inflammatory (gadolinium-enhancing) brain lesions over 6–12 months. MS is naturally variable, so separating stem-cell effects from disease fluctuation or concurrent disease-modifying drugs is difficult without controls. No trial has shown stem cells to be superior to established MS therapies; long-term data are sparse.
Depending on assessment, a Multiple Sclerosis protocol may draw on:
Indicative European costs are roughly €4,500–€7,500 per course, reflecting manufacturing, sterility testing, and often multiple doses. MS patients usually need MRI before and after, and intrathecal (spinal) delivery may require hospitalisation, raising the total. Established MS disease-modifying therapies cost roughly €800–€3,000 monthly via insurance and are proven — the stem-cell figure is indicative and unproven.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Multiple Sclerosis cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Multiple Sclerosis.
Full Multiple Sclerosis FAQ → · Multiple Sclerosis cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite